Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Johnson & Johnson (JNJ) stock is in focus as the FDA greenlights the company's Rybrevant injectable developed with Halozyme ...

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.Over 80% of lung ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to fight ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...